South Africa has a significant hepatitis B burden: an estimated 5–8% of the South African population is chronically infected with hepatitis B virus (HBV), though many remain undiagnosed. Acute hepatitis B with liver failure is a PMB emergency, and hepatocellular carcinoma (liver cancer) is a PMB cancer condition. Chronic hepatitis B, however, is not on the Chronic Disease List (CDL), and whether your scheme funds ongoing antiviral treatment and monitoring from risk depends on its chronic-condition rules — so confirming your cover matters. The distinction between acute infection (self-limiting in most adults), chronic carrier state, and chronic active hepatitis B requiring antiviral treatment determines what your scheme must fund — and at what level.
What Is Hepatitis B?
Hepatitis B is a viral infection caused by the hepatitis B virus (HBV), affecting the liver. HBV is far more infectious than HIV.
Transmission: - Sexual contact (vaginal, anal) - Sharing needles or other injecting equipment - Mother-to-child transmission (perinatal — the most common route globally) - Blood-to-blood contact — needle-stick injuries, shared razors or toothbrushes - Blood transfusions (rare in SA since screening began)
Acute vs chronic HBV: - Acute HBV: Adults infected as adults clear the virus spontaneously 90–95% of the time. Symptoms (if any): jaundice, nausea, abdominal pain, extreme fatigue. - Chronic HBV: Infection acquired perinatally or in early childhood rarely clears; 90% of perinatally infected infants become chronically infected. Chronic infection persists for life and can progress to cirrhosis and hepatocellular carcinoma (HCC).
Key markers: - HBsAg (hepatitis B surface antigen) — positive = infected (acute or chronic) - HBeAg / HBV DNA — markers of active viral replication; high HBV DNA = high infectivity + liver damage - Anti-HBs — indicates immunity (vaccination or prior infection cleared) - Anti-HBc IgM — marker of recent/acute infection
Is Hepatitis B a PMB Condition? — Partly
Hepatitis B is PMB-partial. It depends on which form of the disease you have.
- Acute hepatitis B with liver failure is a PMB emergency. Your scheme must fund hospital admission and management (the Regulations list "ACUTE NECROSIS OF LIVER" and "LIVER FAILURE" as PMB conditions).
- Hepatocellular carcinoma (HCC / liver cancer) is a PMB cancer condition ("CANCER OF LIVER, BILIARY SYSTEM AND PANCREAS — TREATABLE").
- Chronic hepatitis B (ongoing antiviral therapy and monitoring) is not on the Chronic Disease List, and it is not a named chronic Diagnosis-and-Treatment Pair in the Regulations. Whether your scheme funds lifelong antivirals and surveillance from risk depends on its own chronic-condition rules — confirm this with your scheme rather than assuming it is automatic.
Your scheme should fund the initial diagnostic workup (liver function tests, HBV serology, HBV DNA) needed to establish the diagnosis and stage the disease.
How Does Medical Aid Cover Hepatitis B?
| Service | Funded? | Typical cover | Notes |
|---|---|---|---|
| HBV serology (HBsAg, HBeAg, anti-HBs, anti-HBc) | Yes — PMB (diagnostic) | Pathology benefit | Diagnosis and status confirmation |
| HBV DNA (viral load) | Yes — PMB (diagnostic) | Pathology benefit | Guides treatment decision; R600–R1,500/test |
| Liver function tests (ALT, AST, bilirubin, albumin) | Scheme-dependent | Chronic/monitoring benefit | Ongoing monitoring 2–6 monthly; confirm with your scheme |
| Liver biopsy or FibroScan (fibrosis staging) | Yes — PMB (diagnostic) | Hospital/procedure benefit | For treatment decision and staging |
| Hospital admission (acute hepatitis B / liver failure) | Yes — PMB (emergency) | Hospital benefit | For severe acute hepatitis with liver failure |
| Tenofovir disoproxil fumarate (TDF — first-line antiviral) | Scheme-dependent | Chronic medication benefit | Generic available; R200–R600/month; lifelong; not a CDL/DTP entitlement — confirm cover |
| Entecavir (alternative antiviral) | Scheme-dependent | Chronic medication benefit | R400–R900/month; for TDF-intolerant patients; confirm cover |
| Pegylated interferon (time-limited treatment option) | Scheme-dependent | Specialist/formulary | Selected patients; expensive; finite treatment; confirm cover |
| 6-monthly liver ultrasound (HCC surveillance) | Scheme-dependent | Radiology benefit | Surveillance for chronic HBV; confirm cover. HCC treatment, if cancer is found, is PMB |
| Serum AFP (alpha-fetoprotein — HCC marker) | Scheme-dependent | Pathology benefit | HCC surveillance; confirm cover |
| Hepatitis B vaccine (HBV-naive contacts, healthcare workers) | No (prophylaxis) | Prevention benefit (varies) | 3-dose series; R300–R600/dose OOP if not covered |
Antiviral Treatment — Who Qualifies?
Not all chronic HBV carriers require antiviral treatment. The decision is based on:
- HBV DNA level (viral load): >2,000 IU/mL is a common threshold
- ALT level (liver inflammation marker): elevated = liver damage occurring
- Degree of liver fibrosis (FibroScan or biopsy): significant fibrosis = treat regardless of other criteria
- HBeAg status and phase of infection
First-line in SA: Tenofovir disoproxil fumarate (TDF) — 300mg daily. Generic tenofovir is the same drug used for HIV (it suppresses both viruses); generics are widely available and affordable in SA. TDF is the first-line antiviral for chronic HBV; whether it is funded from risk depends on your scheme's chronic-condition rules — chronic HBV is not a CDL condition, so confirm cover with your scheme.
Treatment duration: For most patients with chronic HBV, treatment is lifelong or very long-term. There is no cure for chronic HBV — antivirals suppress viral replication but do not eradicate the virus.
Occupational Risk — Healthcare Workers
Healthcare workers are at elevated occupational risk of HBV infection through needle-stick and blood exposure.
Prevention: HBV vaccination is mandatory for healthcare workers in SA. All healthcare workers should be vaccinated and serologically confirmed immune (anti-HBs titre ≥10 mIU/mL).
Post-exposure prophylaxis (PEP): Following a needle-stick injury with HBV-positive blood source in an unvaccinated or non-immune HCW: hepatitis B immunoglobulin (HBIG) + hepatitis B vaccination within 24 hours is effective. COIDA covers occupationally acquired HBV.
Medical aid coverage: HBIG and accelerated HBV vaccination post-occupational exposure are PMB-covered.
HBV and HIV Co-infection — SA Context
HIV/HBV co-infection is common in SA. Both tenofovir and emtricitabine/lamivudine (components of first-line ART) are active against HBV. SA HIV guidelines incorporate HBV-active ART for co-infected patients.
For HIV/HBV co-infected medical aid members: HIV is a CDL condition, and the first-line ARV regimen (containing tenofovir) is active against HBV as well — so co-infected members on ART typically have their HBV suppressed by their HIV CDL treatment. (HBV on its own is not a CDL condition.)
Key Questions to Ask Your Scheme
- Does my scheme fund chronic Hepatitis B treatment from risk, and how do I register for it? Chronic HBV is not a CDL condition, so cover depends on your scheme's chronic-condition rules — ask once HBsAg-positive status and chronic infection are confirmed.
- Is tenofovir (TDF) covered for my chronic Hepatitis B, and under which benefit?
- Is 6-monthly liver ultrasound (HCC surveillance) covered, and under which benefit?
- If I am a healthcare worker with a needle-stick — is HBIG available through my scheme emergency cover?
Talk to Eldon
Acute hepatitis B and its complications (liver failure, liver cancer) carry PMB protection, but chronic HBV is not a CDL condition — so funding for ongoing antivirals and surveillance varies by scheme. AURA confirms exactly how your scheme covers chronic hepatitis B and ensures monitoring is coded correctly so it is not incorrectly rejected.
See which plans pay for Hepatitis B management →